| Overview |
| bs-12442R-PerCP-Cy5.5 |
| ABLIM3 Polyclonal Antibody, PerCP-Cy5.5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Horse, Rabbit |
| Specifications |
| PerCP-Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ABLIM3 |
| 101-200/683 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 22885 |
| Cytoplasm |
| abLIM-3; Ablim3; ABLM3_HUMAN; Actin binding LIM protein 3; Actin binding LIM protein family member 3; Actin-binding LIM protein 3; Actin-binding LIM protein family member 3; HMFN1661; KIAA0843. |
| The ABLIM1 protein has an N-terminal domain that contains four double zinc finger motifs, which conform to the LIM motif consensus sequence. ABLIM1 binds to F-Actin through a dematin-like domain and is expressed in retina, brain and muscle tissue. There are four known isoforms of ABLIM1. The gene encoding ABLIM1 maps to a region of chromosome 10 associated with frequent loss of heterozygosity in human tumors, thus identifying ABLIM1 as a candidate tumor suppressor gene. ABLIM2 and ABLIM3 show highest expression in muscle and neuronal tissues, bind to F-Actin, and are localized on stress fibers. They also have been shown to enhance STARS (striated muscle activator of Rho signaling) dependent activation of serum-response factor (SRF), thereby modulating transcription. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz